The overall number of short positions in Enanta Pharmaceuticals, Inc. significantly declined during August, resulting in a smaller total number of short positions (NASDAQ: ENTA). As of August 15, the total number of shorted shares was 1,530,000, representing an 8.9% decrease compared to the total number of 1,680,000 shares that were shorted the day before.
The current short-interest ratio is 6.1 days, computed based on an average daily volume of 249,500 shares. This ratio has been around for quite some time. 7.9% of the company’s shares are being sold short by investors. Over the past few months, ENTA has attracted the attention of various research companies. On May 11, Roth Capital lowered its price target for Enanta Pharmaceuticals shares from $101.00 to $70.00. Before this adjustment, the pricing goal was set at $101.00.
As part of a research report released on Tuesday, August 9, JMP Securities raised their rating of the company to “market outperform” and increased their target price on Enanta Pharmaceuticals shares from $103.00 to $137.00. The report was about the company that was named Enanta Pharmaceuticals. In a report released on Wednesday, August 10, Oppenheimer upgraded their rating on Enanta Pharmaceuticals from “market performs” to “outperform” in a report that was In addition, they increased their price target for the company’s shares from $53.00 to $59.00. Both of these changes were made in light of new information. SVB Leerink upgraded their rating on Enanta Pharmaceuticals from “market performs” to “outperform” in a report released on Monday, August 1.
Additionally, they increased their price target for the company’s stock from $44.00 to $50.00. Both of these changes were included in the report. In a research report that was published on Wednesday, July 6, Evercore ISI upgraded Enanta Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a target price of $62.00 for the company in a research report that was The data that Bloomberg supplied indicates that the consensus on Enanta Pharmaceuticals is that it represents a “Moderate Buy,” with an average price goal of $78.63 being projected for the stock. There have been five analysts who have recommended buying the company, and there have been four who have recommended maintaining ownership of it.
Recent changes have been made to ENTA, L.P., and R.A holdings. Capital Management by various institutional investors. These changes were made in the past several months. Enanta Pharmaceuticals invested $68.63 million throughout the first three months of 2018 to purchase a new holding. During the second quarter, State Street Corporation’s stakes in Enanta Pharmaceuticals grew by 29.9%. State Street Corp now owns 1,699,428 shares of the biotechnology company, valued at $80,332,000, after purchasing an additional 390,842 shares during the most recent quarter. During the first three months of 2018, Deep Track Capital L.P. made a new investment in Enanta Pharmaceuticals worth $14,146,000. In the final quarter of 2018, Invesco Ltd. boosted the amount of Enanta Pharmaceuticals stock owned by 173.0%, bringing its total ownership percentage to 100%.
After purchasing 183,676 shares of the biotechnology company’s stock during the preceding quarter, Invesco Ltd. now holds 289,844 shares of the company’s stock. These shares’ combined value equals a total of $21,674,000. Last but certainly not least, Darwin Global Management Ltd. invested $12,428,000 in Enanta Pharmaceuticals during the fourth quarter of 2018 to acquire a new holding in the firm. The stock is owned by hedge funds and other types of institutional investors to the tune of 97.09 percent. When trading started on Wednesday, the price of a share of Enanta Pharmaceuticals was $59.91.
This company’s simple moving average over the last fifty days is $56.97, and the simple moving average over the past two hundred days for this stock is $58.74. Enanta Pharmaceuticals saw a low of $37.59 over the past year, while the business reached a high of $102.00 over the same period. On August 8, shareholders and other interested parties were given access to Enanta Pharmaceuticals (NASDAQ: ENTA) most recent quarterly report. The biotechnology company reported earnings per share (EPS) for the quarter of ($1.53), which was $0.17 less than what was expected by the consensus, which was ($1.36) The sales for the company for the quarter came in at $19.48 million, which was a considerable decrease from the $20.73 million that industry analysts had thought the company would post.
Enanta Pharmaceuticals had a negative return on equity, 32.42%, and a negative net margin, 134.21%. The revenue that was brought in by Enanta Pharmaceuticals during the third quarter fell by 9.9% compared to the same period last year. The corporation incurred $1.19 per share during the same year. Equity research experts believe that Enanta Pharmaceuticals’ earnings for the current fiscal year will equal 5.75 cents per share. This is the amount that is anticipated to be earned by the company. Enanta Pharmaceuticals, Inc. is a biotechnology company responsible for conducting research and developing small-molecule medications to treat liver disorders and viral infections.
The company’s research and development efforts are focused on various infectious diseases, including human metapneumovirus, respiratory syncytial virus, SARS-CoV-2, and hepatitis B virus, amongst others. The company has formed a partnership with Abbott Laboratories for development and licensing. The medications paritaprevir and glecaprevir are included in these treatments.
